Top

BMC Pediatrics

Published in:

Open Access 01-12-2024 | Cranial MRI | Case Report

A case report of peroneal muscle atrophy type 2A2 with central nervous system involvement as initial presentation

Authors: Xin Xu, Fen Lu, Senjie Du, Li Zhang

Published in: BMC Pediatrics | Issue 1/2024

Abstract

Background

Charcot-Marie-Tooth disease (CMT) is a group of single-gene hereditary diseases of peripheral nerve with high clinical variability and genetic heterogeneity. The typical clinical manifestations include progressive muscle weakness and muscle atrophy in the distal extremities, accompanied by disappearance of tendon reflexes and distal sensory disturbances. CMT2A2 (OMIM: 609260) is caused by the mutation of MFN2 (OMIM: 608507), is the most common type of axonal pattern. Although a small number of patients with X-linked CMT1 (CMT1X) present with central nervous system involvement, including reversible white matter lesions, it is rarely in CMT2A2.

Case presentation

A 3-year and 5-month-old girl had experienced motor lag, muscle tension, and abnormal gait for over a year. A reexamination of cranial MRI revealed an anterior enlargement of the abnormal signal range in the lateral ventricles and bilateral frontal lobes. And the whole exon sequencing showed that this girl carried a heterozygous missense mutation c.314C > T of MNF2 gene, inherited from her mother.

Conclusions

In this study, we retrospectively analyzed the clinical and molecular genetic findings of a child with Charcot-Marie-Tooth disease A2 with central nervous system involvement as the initial presentation, and explored its pathogenic mechanism.

Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013;9(10):562–71.CrossRefPubMed

Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Correction: technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2021;23(11):2230.CrossRefPubMed

Bombelli F, Stojkovic T, Dubourg O, Echaniz-Laguna A, Tardieu S, Larcher K, et al. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features. JAMA Neurol. 2014;71(8):1036–42.CrossRefPubMed

Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology. 2005;65(2):197–204.CrossRefPubMed

Detmer SA, Chan DC. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations. J Cell Biol. 2007;176(4):405–14.CrossRefPubMedPubMedCentral

Detmer SA, Velde CV, Cleveland DW, Chan DC. Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot-Marie-Tooth type 2A. Hum Mol Genet. 2008;17(3):367–75.CrossRefPubMed

Youle RJ, Van Der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337(6098):1062–5.CrossRefPubMedPubMedCentral

Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160(2):189–200.CrossRefPubMedPubMedCentral

Dorn GW. Mitofusin 2 dysfunction and disease in mice and men. Front Physiol. 2020;11:782.CrossRefPubMedPubMedCentral

10.

Filadi R, Pendin D, Pizzo P. Mitofusin 2: from functions to disease. Cell Death Dis. 2018;9(3):330.CrossRefPubMedPubMedCentral

11.

Chung K, Kim S, Park K, Choi K, Lee J, Eun H, et al. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain. 2006;129(8):2103–18.CrossRefPubMed

12.

Boaretto F, Vettori A, Casarin A, Vazza G, Muglia M, Rossetto M, et al. Severe CMT type 2 with fatal encephalopathy associated with a novel MFN2 splicing mutation. Neurology. 2010;74(23):1919–21.CrossRefPubMed

13.

Brockmann K, Dreha-Kulaczewski S, Dechent P, Bönnemann C, Helms G, Kyllerman M, et al. Cerebral involvement in axonal Charcot-Marie-Tooth neuropathy caused by mitofusin2 mutations. J Neurol. 2008;255:1049–58.CrossRefPubMed

14.

Verhoeven K, Claeys KG, Züchner S, Schröder JM, Weis J, Ceuterick C, et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain. 2006;129(8):2093–102.CrossRefPubMed

15.

Stuppia G, Rizzo F, Riboldi G, Del Bo R, Nizzardo M, Simone C, et al. MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives. J Neurol Sci. 2015;356(1–2):7–18.CrossRefPubMed

16.

Xiaohui Q, Yuexing L, Daojun H, Yun Y. Clinical and pathological characteristics of a family with Xiake-Mali-Tues disease 2A2 subtype. Chin J Neurol. 2010;43(5):4.

17.

Xiaohui D, Weihong G, Klein CJ, Ying H, Guoxiang W, Renbin W, et al. Phenotypic analysis of 2A2 subtype of Xiake-Mali-Weiss disease caused by mitochondrial fusion protein 2 gene mutation. Chin J Neurol. 2014;2:7.

18.

Jialu X, Yi Z, Congying Z, Peifang J, Zhefeng Y, Yonglin Y, et al. Study on genotyping of 13 cases of early onset peroneal muscle atrophy. Chin J Contemp Pediatr. 2019;21(7):670–5.

19.

Bannerman P, Burns T, Xu J, Miers L, Pleasure D. Mice hemizygous for a pathogenic mitofusin-2 allele exhibit hind limb/foot gait deficits and phenotypic perturbations in nerve and muscle. PLoS ONE. 2016;11(12):0167573.CrossRef

Title: A case report of peroneal muscle atrophy type 2A2 with central nervous system involvement as initial presentation
Authors: Xin Xu
Fen Lu
Senjie Du
Li Zhang
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Cranial MRI
Published in: BMC Pediatrics / Issue 1/2024
Electronic ISSN: 1471-2431
DOI: https://doi.org/10.1186/s12887-023-04441-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A case report of peroneal muscle atrophy type 2A2 with central nervous system involvement as initial presentation

Abstract

Background

Case presentation

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Detection of a novel gross deletion in the UNC13D gene ends the diagnostic odyssey for a family with familial hemophagocytic lymphohistiocytosis 3

Factors influencing necrotizing enterocolitis in premature infants in China: a systematic review and meta-analysis

A novel pyroptosis-related gene signature exhibits distinct immune cells infiltration landscape in Wilms’ tumor

The role of genetic factors in pediatric myelodysplastic syndromes with different outcomes

Antibiotic use in infants at risk of early-onset sepsis: results from a unicentric retrospective cohort study

Risk factors for PDA ligation and neurodevelopmental outcomes at corrected 18–24 months in very low birth weight infants